Applying Newer Doublets in Practice and Sequencing After Immunotherapy in Advanced RCC

In this segment, the discussion centers on how clinicians are interpreting newer combination data in the context of real world practice. The panel reflects on how regimens such as belzutifan based doublets may be incorporated after prior IO exposure and how cross trial comparisons can complicate decision making.

Panelists acknowledge that while progression free survival improvements are encouraging, real world patients often differ from trial populations. Questions arise around whether to favor combination intensification versus sequential single agent strategies, particularly in patients previously exposed to immunotherapy in either the adjuvant or frontline metastatic setting.

The group discusses the practical layering of therapies, recognizing that many regimens were studied in somewhat cleaner clinical scenarios than those encountered in practice. As more patients receive IO earlier in their disease course, clinicians are increasingly treating a population with prior checkpoint exposure and cumulative toxicity. There is an emphasis on mechanism based reasoning rather than strict algorithmic sequencing. The panel underscores that emerging regimens expand options, but require careful integration rather than reflex adoption.

Overall, this segment highlights the evolving complexity of sequencing in advanced RCC, particularly as new doublets enter the treatment landscape.